Insmed Announces Pricing of Public Offering of Common Stock
September 06, 2017 21:36 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it priced an offering of 12,281,000 shares of its common stock in a registered...
Insmed Announces Proposed Public Offering of Common Stock
September 05, 2017 16:01 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced today that it has commenced an underwritten public offering of $250 million of shares of its common...
Insmed Announces Positive Top-Line Results from Phase 3 CONVERT Study of ALIS (Amikacin Liposome Inhalation Suspension) in Adult Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC)
September 05, 2017 07:00 ET
|
Insmed Incorporated
Study met primary endpoint of culture conversion (p< 0.0001)Positive top-line results from global Phase 3 controlled study in patients with NTM, a rare, progressive, destructive lung infection...
Insmed Reports Second Quarter 2017 Financial Results and Provides Business Update
August 03, 2017 07:30 ET
|
Insmed Incorporated
On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis...
Insmed to Host Second Quarter 2017 Financial Results Conference Call on Thursday, August 3, 2017
July 27, 2017 08:00 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed to Host Analyst and Investor Day on July 19, 2017
July 12, 2017 08:00 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...
Insmed to Present at the JMP Securities Life Sciences Conference
June 13, 2017 08:00 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., June 13, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, announced today...
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 08, 2017 08:00 ET
|
Insmed Incorporated
BRIDGEWATER, N.J., June 08, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
Insmed Announces Key Additions to its Executive Management Team
May 15, 2017 07:00 ET
|
Insmed Incorporated
-- Paolo Tombesi named as Chief Financial Officer ---- Paul Streck, M.D., appointed as Chief Medical Officer ---- Eugene Sullivan, M.D., assumes role of Chief Product Strategy Officer --BRIDGEWATER,...
Insmed Reports First Quarter 2017 Financial Results and Provides Business Update
May 03, 2017 08:02 ET
|
Insmed Incorporated
Advancing Toward Top-Line Results from CONVERT Study in 2H 2017 Conference call today at 8:30 AM ET BRIDGEWATER, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM),...